Drug intelligence / Profile preview

BIO-112

Development stage: Preclinical
Lead developer: BiOneCure Therapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BIO-112 is an antibody-drug conjugate (ADC) being developed by BiOneCure Therapeutics for the treatment of solid tumors. Currently in the lead development stage, BIO-112 is part of a broader pipeline of ADC candidates that utilize the company's proprietary platform technologies. While the specific molecular target and cytotoxic payload for BIO-112 have not yet been disclosed, the drug is designed to selectively deliver a potent therapeutic agent to tumor cells, minimizing systemic toxicity and improving efficacy in various solid tumor indications. The candidate is being positioned as a potential first-in-class or best-in-class therapy within the oncology space.

Beyond the preview

Go deeper on BIO-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BIO-112.

Explore the full profile